According to BioIntel360, diabetes market in France is expected to grow by 11.5% on annual basis to reach US$4,439.5 million in 2025. The diabetes market in the country has experienced robust growth...
According to BioIntel360, diabetes market in France is expected to grow by 11.5% on annual basis to reach US$4,439.5 million in 2025. The diabetes market in the country has experienced robust growth during 2020-2024, achieving a CAGR of 12.4%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 9.7% during 2025-2029. By the end of 2029, the diabetes market is projected to expand from its 2024 value of USD 3,981.4 million to approximately USD 7,112.5 million. Key Trends and Drivers in France The French diabetes devices and therapeutics market is currently influenced by the expanded adoption of CGM, integration of digital health platforms, advancement of therapeutic delivery systems, and evolving regulatory frameworks. Over the next 2–4 years, these trends will intensify, driving improvements in clinical monitoring, remote patient management, and overall treatment precision within the French healthcare system. Expand Continuous Glucose Monitoring Adoption • French healthcare providers are broadening the use of continuous glucose monitoring (CGM) devices within public and private clinical settings. Recent initiatives in regions such as Île-de-France and Auvergne-Rhône-Alpes have integrated CGM systems into diabetes management programs. • Updated reimbursement guidelines and policy reviews by French health authorities have created conditions that favor CGM implementation. Recent publications indicate a shift toward data-centric care in diabetes management, supported by evolving clinical practice protocols and insurance coverage adjustments. • The adoption rate of CGM devices is projected to increase as reimbursement structures expand and clinical evidence reinforces their use. This trend is expected to intensify, resulting in improved monitoring capabilities and more informed treatment adjustments across French healthcare settings. Integrate Digital Health Solutions for Remote Management • French healthcare institutions are incorporating digital platforms to support remote monitoring and telemedicine in diabetes care. Examples include pilot programs using centralized digital dashboards that consolidate patient data for enhanced clinical decision-making in select French hospitals. • Government-backed digital health initiatives and regulatory updates over the past year have streamlined the integration of remote monitoring tools. Broader trends in the MedTech industry—such as increased funding for telemedicine and changes in healthcare delivery—are influencing the uptake of these digital solutions. • Digital health solutions are expected to expand, driven by policy enhancements and demonstrated benefits in patient management. Enhanced connectivity between patients and providers is anticipated to sustain this trend, resulting in more efficient diabetes care practices. Advance Therapeutic Delivery Systems • New therapeutic devices, including smart insulin pens and connected insulin pumps, are emerging in the French market. Recent clinical trials and pilot studies in French healthcare centers have assessed these systems for improved dosing accuracy and treatment adherence. • Technological progress and supportive findings from recent local studies are driving the development and acceptance of these therapeutic systems. As reported in recent publications, adjustments in reimbursement policies and MedTech investment trends are facilitating their adoption. • The penetration of advanced therapeutic delivery systems is expected to intensify as clinical guidelines evolve, and insurers adapt to new reimbursement models. Over the medium term, these devices may contribute to more precise treatment regimens and improved patient outcomes in France. Regulatory and Reimbursement Frameworks • French regulatory bodies are updating approval processes and reimbursement frameworks to accommodate new diabetes devices and therapeutic technologies. Recent policy documents highlight integrating digital and connected medical devices within national healthcare programs. • Broader healthcare reform initiatives and cost-containment measures are prompting these regulatory adjustments. Recent reports from French health agencies underline the need for a clearer pathway to support innovative, cost-effective diabetes management solutions. • A more defined regulatory framework is expected to enhance market confidence, leading to increased investment and adoption of advanced devices. Over the next few years, the impact of regulatory evolution is likely to intensify, paving the way for consistent market growth and improved patient access to new technologies. Competitive Landscape in France Multinational leaders and emerging local companies mark the French market, each contributing to the range of diabetes devices and therapeutic solutions available. Strategic partnerships, mergers, and acquisitions reshape competitive dynamics to enhance digital integration and regulatory alignment. Looking forward, the competitive environment is set to intensify over the next 2–4 years, driving innovation and more precise patient management practices in the French diabetes sector. Current Market Conditions • The French diabetes devices and therapeutics market combines longstanding multinational companies with emerging local firms. It spans many products, from continuous monitoring devices to connected therapeutic delivery systems, and is supported by a robust public healthcare framework. Key Players and New Entrants • Major multinational manufacturers have a significant presence in France, benefiting from established distribution networks and partnerships with local healthcare institutions. These players offer comprehensive portfolios that address both monitoring and therapeutic needs. • Local startups and smaller companies are entering the market with digital health solutions designed specifically for French patient populations. Recent market analyses indicate that these entrants are gaining traction through pilot programs and niche product offerings. Review Recent Partnerships, Mergers, and Acquisitions • Recent publications have reported strategic partnerships between established and local technology firms to enhance digital connectivity and device interoperability. Mergers and acquisitions in the past 12 months signal a trend toward consolidating technological expertise and market reach, with several key transactions designed to optimize product development. • These collaborative efforts lead to a more interconnected market, where shared innovation and joint ventures support faster technology deployment. Such activities contribute to more efficient regulatory compliance and enhanced product offerings tailored to the French healthcare environment. Future Competitive Dynamics (Next 2–4 Years) • The competitive landscape is expected to evolve with increased consolidation as established players strengthen their digital health portfolios and new entrants secure strategic alliances. Industry reports suggest a clear segmentation between companies focused on traditional device offerings and those emphasizing digital integration. • Over the next few years, intensified competition and strategic consolidations are likely to drive targeted innovations and further refine patient management solutions. This evolution is expected to enhance market efficiency and broaden access to advanced diabetes care solutions within France. This report provides a detailed data-centric analysis of the diabetes industry in France, covering market opportunities and analysis across a range of diagnosis and monitoring devices, therapeutics, domains. With over 50+ KPIs at the country level, this report provides a comprehensive understanding of diabetes market dynamics, market size and forecast, and market share statistics. BioIntel360’s research methodology is based on industry best practices. Its unbiased analysis leverages a proprietary analytics platform to offer a detailed view of emerging business and investment market opportunities.
This report provides an in-depth, data-centric analysis of the France diabetes devices and therapeutics market 2020-2029. Below is a summary of key market segments: Diabetes Devices and Therapeutics Market Share by Category • Diagnosis and Monitoring Devices • Therapeutics Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices • Blood Glucose Monitoring Devices • Insulin Delivery Devices • Diabetes Management and Mobile Applications • Artificial Pancreas Devices Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices • Self-Monitoring Blood Glucose Devices • Continuous Blood Glucose Monitoring Devices • Test Strips • Lancets Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices • Insulin Pumps • Insulin Pens • Insulin Syringes Diabetes Devices and Therapeutics Market Share by Therapeutics • Oral Anti-Diabetic Drugs • Insulin • Non-Insulin Injectable Drugs • Combination Drugs Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs • Alpha-Glucosidase Inhibitors • DPP-4 Inhibitors • SGLT-2 Inhibitors Diabetes Devices and Therapeutics Market Share by Insulin • Basal or Long-Acting • Bolus or Fast-Acting • Traditional Human Insulin Drugs • Insulin Biosimilars Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs • GLP-1 Receptor Agonists • Amylin Analogue Diabetes Devices and Therapeutics Market Share by Combination Drugs • Combination Insulin • Oral Combination Diabetes Devices and Therapeutics Market Share by Route of Administration • Subcutaneous • Intravenous • Others Diabetes Devices and Therapeutics Market Share by Type of Diabetes • Type 1 Diabetes • Type 2 Diabetes Diabetes Devices and Therapeutics Market Share by Distribution Channels • Online Pharmacies • Hospital Pharmacies • Retail Pharmacies Diabetes Devices and Therapeutics Market Share by End User • Hospitals • Diabetes Clinics • Homecare
• Comprehensive understanding of market structure and dynamics: Gain a detailed view of the diabetes devices and therapeutics market, including category-level segmentation (Diagnosis & Monitoring Devices and Therapeutics) and sub-segmentation by product type, route of administration, type of diabetes, distribution channel, and end user. • Identify high-growth segments and strategic investment areas: Use segment-wise market sizing and forecasting to identify opportunities in areas such as continuous glucose monitoring, insulin delivery technologies, oral anti-diabetic drugs, and biosimilars. Tailor your market entry or expansion strategies accordingly. • Benchmark performance across distribution and care settings: Access share analysis across online, hospital, and retail pharmacies, and evaluate usage patterns across hospitals, diabetes clinics, and homecare to support channel-specific planning and resource allocation.
1 France Diabetes Devices and Therapeutics Market Size and Forecast, 2020-2029 2 France Diabetes Devices and Therapeutics Market Share by Category, 2020-2029 2.1 France Diabetes Devices and Therapeutics Market Size by Diagnosis and Monitoring Devices, 2020-2029 2.2 France Diabetes Devices and Therapeutics Market Size by Therapeutics, 2020-2029 3 France Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices, 2020-2029 3.1 Diabetes Devices and Therapeutics Market Size by Blood Glucose Monitoring Devices, 2020-2029 3.2 Diabetes Devices and Therapeutics Market Size by Insulin Delivery Devices, 2020-2029 3.3 Diabetes Devices and Therapeutics Market Size by Diabetes Management and Mobile Applications, 2020-2029 3.4 Diabetes Devices and Therapeutics Market Size by Artificial Pancreas Devices, 2020-2029 4 France Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices, 2020-2029 4.1 Diabetes Devices and Therapeutics Market Size by Self-Monitoring Blood Glucose Devices, 2020-2029 4.2 Diabetes Devices and Therapeutics Market Size by Continuous Blood Glucose Monitoring Devices, 2020-2029 4.3 Diabetes Devices and Therapeutics Market Size by Test Strips, 2020-2029 4.4 Diabetes Devices and Therapeutics Market Size by Lancets, 2020-2029 5 France Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices, 2020-2029 5.1 Diabetes Devices and Therapeutics Market Size by Insulin Pumps, 2020-2029 5.2 Diabetes Devices and Therapeutics Market Size by Insulin Pens, 2020-2029 5.3 Diabetes Devices and Therapeutics Market Size by Insulin Syringes, 2020-2029 6 France Diabetes Devices and Therapeutics Market Share by Therapeutics, 2020-2029 6.1 Diabetes Devices and Therapeutics Market Size by Oral Anti-Diabetic Drugs, 2020-2029 6.2 Diabetes Devices and Therapeutics Market Size by Insulin, 2020-2029 6.3 Diabetes Devices and Therapeutics Market Size by Non-Insulin Injectable Drugs, 2020-2029 6.4 Diabetes Devices and Therapeutics Market Size by Combination Drugs, 2020-2029 7 France Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs, 2020-2029 7.1 Diabetes Devices and Therapeutics Market Size by Alpha-Glucosidase Inhibitors, 2020-2029 7.2 Diabetes Devices and Therapeutics Market Size by DPP-4 Inhibitors, 2020-2029 7.3 Diabetes Devices and Therapeutics Market Size by SGLT-2 Inhibitors, 2020-2029 8 France Diabetes Devices and Therapeutics Market Share by Insulin, 2020-2029 8.1 Diabetes Devices and Therapeutics Market Size by Basal or Long-Acting, 2020-2029 8.2 Diabetes Devices and Therapeutics Market Size by Bolus or Fast-Acting, 2020-2029 8.3 Diabetes Devices and Therapeutics Market Size by Traditional Human Insulin Drugs, 2020-2029 8.4 Diabetes Devices and Therapeutics Market Size by Insulin Biosimilars, 2020-2029 9 France Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs, 2020-2029 9.1 Diabetes Devices and Therapeutics Market Size by GLP-1 Receptor Agonists, 2020-2029 9.2 Diabetes Devices and Therapeutics Market Size by Amylin Analogue, 2020-2029 10 France Diabetes Devices and Therapeutics Market Share by Combination Drugs, 2020-2029 10.1 Diabetes Devices and Therapeutics Market Size by Combination Insulin, 2020-2029 10.2 Diabetes Devices and Therapeutics Market Size by Oral Combination, 2020-2029 11 France Diabetes Devices and Therapeutics Market Share by Route of Administration, 2020-2029 11.1 Diabetes Devices and Therapeutics Market Size by Subcutaneous, 2020-2029 11.2 Diabetes Devices and Therapeutics Market Size by Intravenous, 2020-2029 11.3 Diabetes Devices and Therapeutics Market Size by Others, 2020-2029 12 France Diabetes Devices and Therapeutics Market Share by Type of Diabetes, 2020-2029 12.1 Diabetes Devices and Therapeutics Market Size by Type 2 Diabetes, 2020-2029 12.2 Diabetes Devices and Therapeutics Market Size by Type 1 Diabetes, 2020-2029 13 France Diabetes Devices and Therapeutics Market Share by Distribution Channels, 2020-2029 13.1 Diabetes Devices and Therapeutics Market Size by Online Pharmacies, 2020-2029 13.2 Diabetes Devices and Therapeutics Market Size by Hospital Pharmacies, 2020-2029 13.3 Diabetes Devices and Therapeutics Market Size by Retail Pharmacies, 2020-2029 14 France Diabetes Devices and Therapeutics Market Share by End User, 2020-2029 14.1 Diabetes Devices and Therapeutics Market Size by Hospitals, 2020-2029 14.2 Diabetes Devices and Therapeutics Market Size by Diabetes Clinics, 2020-2029 14.3 Diabetes Devices and Therapeutics Market Size by Homecare, 2020-2029
Table 1: France Diabetes Devices and Therapeutics Market Size by Value (US$ Million) 2020-2029 Table 2: France Diabetes Devices and Therapeutics Market Size by Diagnosis and Monitoring Devices, by Value (US$ Million), 2020-2029 Table 3: France Diabetes Devices and Therapeutics Market Size by Therapeutics, by Value (US$ Million) 2020-2029 Table 4: France Diabetes Devices and Therapeutics Market Size by Blood Glucose Monitoring Devices, by Value (US$ Million) 2020-2029 Table 5: France Diabetes Devices and Therapeutics Market Size by Insulin Delivery Devices, by Value (US$ Million) 2020-2029 Table 6: France Diabetes Devices and Therapeutics Market Size by Diabetes Management and Mobile Applications, by Value (US$ Million) 2020-2029 Table 7: France Diabetes Devices and Therapeutics Market Size by Artificial Pancreas Devices, by Value (US$ Million) 2020-2029 Table 8: France Diabetes Devices and Therapeutics Market Size by Self-Monitoring Blood Glucose Devices, by Value (US$ Million) 2020-2029 Table 9: France Diabetes Devices and Therapeutics Market Size by Continuous Blood Glucose Monitoring Devices, by Value (US$ Million) 2020-2029 Table 10: France Diabetes Devices and Therapeutics Market Size by Test Strips, by Value (US$ Million) 2020-2029 Table 11: France Diabetes Devices and Therapeutics Market Size by Lancets, by Value (US$ Million) 2020-2029 Table 12: France Diabetes Devices and Therapeutics Market Size by Insulin Pumps, by Value (US$ Million) 2020-2029 Table 13: France Diabetes Devices and Therapeutics Market Size by Insulin Pens, by Value (US$ Million) 2020-2029 Table 14: France Diabetes Devices and Therapeutics Market Size by Insulin Syringes, by Value (US$ Million) 2020-2029 Table 15: France Diabetes Devices and Therapeutics Market Size by Oral Anti-Diabetic Drugs, by Value (US$ Million), 2020-2029 Table 16: France Diabetes Devices and Therapeutics Market Size by Insulin, by Value (US$ Million), 2020-2029 Table 17: France Diabetes Devices and Therapeutics Market Size by Non-Insulin Injectable Drugs, by Value (US$ Million), 2020-2029 Table 18: France Diabetes Devices and Therapeutics Market Size by Combination Drugs, by Value (US$ Million), 2020-2029 Table 19: France Diabetes Devices and Therapeutics Market Size by Alpha-Glucosidase Inhibitors (US$ Million), 2020-2029 Table 20: France Diabetes Devices and Therapeutics Market Size by DPP-4 Inhibitors (US$ Million), 2020-2029 Table 21: France Diabetes Devices and Therapeutics Market Size by SGLT-2 Inhibitors (US$ Million), 2020-2029 Table 22: France Diabetes Devices and Therapeutics Market Size by Basal or Long-Acting, by Value (US$ Million), 2020-2029 Table 23: France Diabetes Devices and Therapeutics Market Size by Bolus or Fast-Acting, by Value (US$ Million), 2020-2029 Table 24: France Diabetes Devices and Therapeutics Market Size by Traditional Human Insulin Drugs, by Value (US$ Million), 2020-2029 Table 25: France Diabetes Devices and Therapeutics Market Size by Insulin Biosimilars, by Value (US$ Million), 2020-2029 Table 26: France Diabetes Devices and Therapeutics Market Size by GLP-1 Receptor Agonists, by Value (US$ Million), 2020-2029 Table 27: France Diabetes Devices and Therapeutics Market Size by Amylin Analogue, by Value (US$ Million), 2020-2029 Table 28: France Diabetes Devices and Therapeutics Market Size by Combination Insulin, by Value (US$ Million), 2020-2029 Table 29: France Diabetes Devices and Therapeutics Market Size by Oral Combination, by Value (US$ Million), 2020-2029 Table 30: France Diabetes Devices and Therapeutics Market Size by Subcutaneous, by Value (US$ Million), 2020-2029 Table 31: France Diabetes Devices and Therapeutics Market Size by Intravenous, by Value (US$ Million), 2020-2029 Table 32: France Diabetes Devices and Therapeutics Market Size by Others, by Value (US$ Million), 2020-2029 Table 33: France Diabetes Devices and Therapeutics Market Size by Type 2 Diabetes, by Value (US$ Million), 2020-2029 Table 34: France Diabetes Devices and Therapeutics Market Size by Type 1 Diabetes, by Value (US$ Million), 2020-2029 Table 35: France Diabetes Devices and Therapeutics Market Size by Online Pharmacies, by Value (US$ Million), 2020-2029 Table 36: France Diabetes Devices and Therapeutics Market Size by Hospital Pharmacies, by Value (US$ Million), 2020-2029 Table 37: France Diabetes Devices and Therapeutics Market Size by Retail Pharmacies, by Value (US$ Million), 2020-2029 Table 38: France Diabetes Devices and Therapeutics Market Size by Hospitals, by Value (US$ Million), 2020-2029 Table 39: France Diabetes Devices and Therapeutics Market Size by Diabetes Clinics, by Value (US$ Million), 2020-2029 Table 40: France Diabetes Devices and Therapeutics Market Size by Homecare, by Value (US$ Million), 2020-2029
Figure 1: France Diabetes Devices and Therapeutics Market Size by Value (US$ Million) 2020-2029 Figure 2: France Diabetes Devices and Therapeutics Market Share by Category (%), 2020-2029 Figure 3: France Diabetes Devices and Therapeutics Market Size by Diagnosis and Monitoring Devices, by Value (US$ Million), 2020-2029 Figure 4: France Diabetes Devices and Therapeutics Market Size by Therapeutics, by Value (US$ Million) 2020-2029 Figure 5: France Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices (%), 2020-2029 Figure 6: France Diabetes Devices and Therapeutics Market Size by Blood Glucose Monitoring Devices, by Value (US$ Million) 2020-2029 Figure 7: France Diabetes Devices and Therapeutics Market Size, by Insulin Delivery Devices, by Value (US$ Million) 2020-2029 Figure 8: France Diabetes Devices and Therapeutics Market Size by Diabetes Management and Mobile Applications, by Value (US$ Million) 2020-2029 Figure 9: France Diabetes Devices and Therapeutics Market Size, by Artificial Pancreas Devices, by Value (US$ Million) 2020-2029 Figure 10: France Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices (%), 2020-2029 Figure 11: France Diabetes Devices and Therapeutics Market Size by Self-Monitoring Blood Glucose Devices, by Value (US$ Million) 2020-2029 Figure 12: France Diabetes Devices and Therapeutics Market Size by Continuous Blood Glucose Monitoring Devices, by Value (US$ Million) 2020-2029 Figure 13: France Diabetes Devices and Therapeutics Market Size by Test Strips, by Value (US$ Million) 2020-2029 Figure 14: France Diabetes Devices and Therapeutics Market Size by Lancets, by Value (US$ Million) 2020-2029 Figure 15: France Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices (%), 2020-2029 Figure 16: France Diabetes Devices and Therapeutics Market Share by Insulin Pumps, by Value (US$ Million) 2020-2029 Figure 17: France Diabetes Devices and Therapeutics Market Share by Insulin Pens, by Value (US$ Million) 2020-2029 Figure 18: France Diabetes Devices and Therapeutics Market Share by Insulin Syringes, by Value (US$ Million) 2020-2029 Figure 19: France Diabetes Devices and Therapeutics Market Share by Therapeutics (%), 2020-2029 Figure 20: France Diabetes Devices and Therapeutics Market Size by Oral Anti-Diabetic Drugs, by Value (US$ Million), 2020-2029 Figure 21: France Diabetes Devices and Therapeutics Market Size by Insulin, by Value (US$ Million), 2020-2029 Figure 22: France Diabetes Devices and Therapeutics Market Size by Non-Insulin Injectable Drugs, by Value (US$ Million), 2020-2029 Figure 23: France Diabetes Devices and Therapeutics Market Size by Combination Drugs, by Value (US$ Million), 2020-2029 Figure 24: France Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs (%), 2020-2029 Figure 25: France Diabetes Devices and Therapeutics Market Size by Alpha-Glucosidase Inhibitors (US$ Million), 2020-2029 Figure 26: France Diabetes Devices and Therapeutics Market Size by DPP-4 Inhibitors (US$ Million), 2020-2029 Figure 27: France Diabetes Devices and Therapeutics Market Size by SGLT-2 Inhibitors (US$ Million), 2020-2029 Figure 28: France Diabetes Devices and Therapeutics Market Share by Insulin (%), 2020-2029 Figure 29: France Diabetes Devices and Therapeutics Market Size by Basal or Long-Acting, by Value (US$ Million), 2020-2029 Figure 30: France Diabetes Devices and Therapeutics Market Size by Bolus or Fast-Acting, by Value (US$ Million), 2020-2029 Figure 31: France Diabetes Devices and Therapeutics Market Size by Traditional Human Insulin Drugs, by Value (US$ Million), 2020-2029 Figure 32: France Diabetes Devices and Therapeutics Market Size by Insulin Biosimilars, by Value (US$ Million), 2020-2029 Figure 33: France Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs (%), 2020-2029 Figure 34: France Diabetes Devices and Therapeutics Market Size by GLP-1 Receptor Agonists, by Value (US$ Million), 2020-2029 Figure 35: France Diabetes Devices and Therapeutics Market Size by Amylin Analogue, by Value (US$ Million), 2020-2029 Figure 36: France Diabetes Devices and Therapeutics Market Share by Combination Drugs (%), 2020-2029 Figure 37: France Diabetes Devices and Therapeutics Market Size by Combination Insulin, by Value (US$ Million), 2020-2029 Figure 38: France Diabetes Devices and Therapeutics Market Size by Oral Combination, by Value (US$ Million), 2020-2029 Figure 39: France Diabetes Devices and Therapeutics Market Share by Route of Administration (%), 2020-2029 Figure 40: France Diabetes Devices and Therapeutics Market Size by Subcutaneous, by Value (US$ Million), 2020-2029 Figure 41: France Diabetes Devices and Therapeutics Market Size by Intravenous, by Value (US$ Million), 2020-2029 Figure 42: France Diabetes Devices and Therapeutics Market Size by Others, by Value (US$ Million), 2020-2029 Figure 43: France Diabetes Devices and Therapeutics Market Share by Type of Diabetes (%), 2020-2029 Figure 44: France Diabetes Devices and Therapeutics Market Size by Type 2 Diabetes, by Value (US$ Million), 2020-2029 Figure 45: France Diabetes Devices and Therapeutics Market Size by Type 1 Diabetes, by Value (US$ Million), 2020-2029 Figure 46: France Diabetes Devices and Therapeutics Market Share by Distribution Channels (%), 2020-2029 Figure 47: France Diabetes Devices and Therapeutics Market Size by Online Pharmacies, by Value (US$ Million), 2020-2029 Figure 48: France Diabetes Devices and Therapeutics Market Size by Hospital Pharmacies, by Value (US$ Million), 2020-2029 Figure 49: France Diabetes Devices and Therapeutics Market Size by Retail Pharmacies, by Value (US$ Million), 2020-2029 Figure 50: France Diabetes Devices and Therapeutics Market Share by End User (%), 2020-2029 Figure 51: France Diabetes Devices and Therapeutics Market Size by Hospitals, by Value (US$ Million), 2020-2029 Figure 52: France Diabetes Devices and Therapeutics Market Size by Diabetes Clinics, by Value (US$ Million), 2020-2029 Figure 53: France Diabetes Devices and Therapeutics Market Size by Homecare, by Value (US$ Million), 2020-2029
